In this episode, we explore the current clinical applications of poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in cancer care, including their role, targeted cancers, and strategies for managing side effects of these agents. We also forecast where these agents may have additional utilization in the future.
SPEAKERS
Jason Bergsbaken, PharmD, MBA, BCOP currently serves as Pharmacy Coordinator, Regional Oncology Services, UW Health and Clinical Assistant Professor, University of Wisconsin-Madison School of Pharmacy in Madison, WI. Dr. Bergsbaken received his Doctor of Pharmacy degree from the University of Wisconsin-Madison. Following graduation, he completed a PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at UW Health. Dr. Bergsbaken completed a Master of Business Administration degree through University of Wisconsin-Whitewater.
Lizeth Garcia-Jennings, PharmD, received her Doctor of Pharmacy degree from UW-Madison School of Pharmacy. Lizeth is currently a postgraduate year 2 Oncology Pharmacy Resident at UW Health. Lizeth also completed her PGY-1 Acute Care Pharmacy Residency at UW Health. Lizeth’s Oncology interests include Bone Marrow Transplant, hematologic malignancies, Precepting, and Ambulatory Care. Outside of pharmacy, Lizeth enjoys traveling, trying new restaurants, and playing board games with her friends and family.